In the OASIS study, a multicenter observational study that included 74 adult patients with a recent diagnosis of acromegaly, surgery was the first therapeutic option in 76% of patients, persistent or recurrence disease was present in 73% after surgery, and in 90% of them, SSAs were used for disease control (54% as monotherapy), achieving a normalized IGF-1 level in 52% and disease control criteria in 47% of patients. Here, IGF1 is linked to acromegaly.